Physician profile
David Robbins
NPI 1871580738
$4,065.28
in general payments reported to CMS, 2019-2025
33 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $218 · 2021: $116 · 2022: $307 · 2023: $469 · 2024: $1,044 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $510.26 | 2019-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Astrazeneca Pharmaceuticals Lp | $428.81 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $340.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $279.78 | 2023-2025 | Verquvo, Capvaxive |
| Amgen INC. | $268.76 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.04 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.09 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $190.16 | 2019-2024 | Xarelto |
| Irhythm Technologies, INC. | $175.57 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $173.57 | 2019-2025 | Eliquis |
| Pfizer INC. | $162.28 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $124.62 | 2019-2023 | |
| Medtronic, INC. | $103.89 | 2021-2025 | Venaseal, Resolute Onyx |
| Abbott Laboratories | $91.49 | 2021-2024 | Amplatzer Amulet |
| Boston Scientific Corporation | $90.23 | 2019-2024 | Watchman Flx, Watchman Access System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $87.34 | 2025 | Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $58.84 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $57.37 | 2025 | |
| Medtronic Vascular, INC. | $53.49 | 2019-2020 | |
| Abiomed | $50.96 | 2025 | |
| Alnylam Pharmaceuticals INC. | $48.69 | 2019-2024 | Amvuttra |
| Cardiovascular Systems INC. | $44.64 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $42.66 | 2023 | Arcalyst |
| Calyxo, INC. | $33.94 | 2025 | Cvac Aspiration System |
| Shockwave Medical, INC | $28.25 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amarin Pharma, INC. | $28.09 | 2019 | |
| Penumbra, INC. | $21.45 | 2024 | Indigo System |
| Baxter Healthcare | $20.51 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $20.47 | 2023 | |
| Esperion Therapeutics, INC. | $17.18 | 2024 | Nexletol |
| Stryker Corporation | $13.94 | 2025 | Artix Mt |
| Atricure, INC. | $13.66 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.